| Content Provider |
World Health Organization (WHO)-Global Index Medicus |
| Author |
Ujj, Zsófia Buglyó, Gergely Udvardy, Miklós Beyer, Dániel Vargha, György Biró, Sándor Rejto, László |
| Description |
Country affiliation: Hungary Author Affiliation: Ujj Z ( Institute of Internal Medicine, Division of Haematology, University of Debrecen, 98 Nagyerdei körút, Debrecen, 4028, Hungary.); Buglyó G ( Department of Human Genetics, University of Debrecen, 98 Nagyerdei körút, Debrecen, 4028, Hungary. gbuglyo@hotmail.com.); Udvardy M ( Institute of Internal Medicine, Division of Haematology, University of Debrecen, 98 Nagyerdei körút, Debrecen, 4028, Hungary.); Beyer D ( Department of Human Genetics, University of Debrecen, 98 Nagyerdei körút, Debrecen, 4028, Hungary.); Vargha G ( Department of Human Genetics, University of Debrecen, 98 Nagyerdei körút, Debrecen, 4028, Hungary.); Biró S ( Department of Human Genetics, University of Debrecen, 98 Nagyerdei körút, Debrecen, 4028, Hungary.); Rejto L ( Institute of Internal Medicine, Division of Haematology, University of Debrecen, 98 Nagyerdei körút, Debrecen, 4028, Hungary.) |
| Abstract |
Expression of the gene Wilms tumor 1 (WT1) has been suggested as a marker of minimal residual disease in acute myeloid leukemia (AML), but literature data are not without controversy. Our aim was to assess the presence, magnitude and temporal changes of WT1 expression as prognostic factors. 60 AML patients were followed until death or the end of the 6-year observation period. Blood samples were taken at diagnosis, post-induction, during remission and in case of a relapse. Using quantitative real-time PCR, we determined WT1 expression from each sample, normalized it against the endogenous control gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and classified samples as negative, moderately positive or highly positive. We divided the patients into groups based on detected WT1 expression values, illustrated overall and disease-free survival on Kaplan-Meier curves, and compared differences between each group by the logrank test. Disappearance of WT1-positivity during chemotherapy had a favorable effect on survival. Interestingly, no difference was seen between the survivals of WT1-positive subgroups that expressed moderate or high levels of WT1 mRNA. A 1-log decrease in WT1 expression without becoming negative did not affect prognosis, either. Our results suggest that defining a cut-off value for WT1-positivity, rather than just using logarithmic figures of changes in gene expression, might have prognostic use in post-induction AML patients. We encourage further, larger-scale studies. |
| File Format |
HTM / HTML |
| ISSN |
12194956 |
| Issue Number |
1 |
| Volume Number |
22 |
| e-ISSN |
15322807 |
| Journal |
Pathology & Oncology Research |
| Language |
English |
| Publisher |
Springer |
| Publisher Date |
2016-01-01 |
| Publisher Place |
Netherlands |
| Access Restriction |
Subscribed |
| Subject Keyword |
Discipline Oncology Tumor Markers, Biological Genetics Leukemia, Myeloid, Acute Pathology Wt1 Proteins Adult Aged Aged, 80 And Over Antineoplastic Combined Chemotherapy Protocols Therapeutic Use Female Flow Cytometry Follow-up Studies Humans Drug Therapy Male Middle Aged Neoplasm Staging Neoplasm, Residual Prognosis Rna, Messenger Real-time Polymerase Chain Reaction Reverse Transcriptase Polymerase Chain Reaction Survival Rate Young Adult Journal Article Research Support, Non-u.s. Gov't |
| Content Type |
Text |
| Resource Type |
Article |
| Subject |
Cancer Research Pathology and Forensic Medicine Oncology |
